- GlobeNewswire•21 days agoSanthera announces appointment of Kristina Timdahl as Chief Medical Officer and Head of Development as of January 2017
Liestal, Switzerland, October 4, 2016 - Santhera Pharmaceuticals (SIX: SANN) announces the appointment of Kristina Timdahl, MD, as Chief Medical Officer and Head of Development and Member of the Executive ...
- GlobeNewswire•27 days agoSanthera Starts Phase III Study (SIDEROS) with Raxone in Patients with Duchenne Muscular Dystrophy Using Glucocorticoids
Liestal, Switzerland, September 28, 2016 - Santhera Pharmaceuticals (SIX: SANN) announces that the first patient has been enrolled at the University of Kansas Medical Center (KUMC), Department of Neurology, ...
- GlobeNewswire•last monthLeading medical journal publishes treatment effect of Santhera's Raxone on inspiratory function in patients with Duchenne muscular dystrophy (DMD)
Liestal, Switzerland, September 13, 2016 - Santhera Pharmaceuticals (SIX: SANN) announces that additional data from the pivotal phase III trial (DELOS) demonstrating efficacy of Raxone (idebenone) on inspiratory ...
SANTHERA N (SANN.SW)
Swiss - Swiss Delayed Price. Currency in CHF
|Day's Range||48.50 - 49.80|
|52wk Range||47.15 - 107.60|
|1y Target Est||N/A|
|P/E Ratio (ttm)||N/A|
|Avg Vol (3m)||13,988|
|Dividend & Yield||N/A (N/A)|